Jefferies Reiterates Buy Rating on Arcutis Biotherapeutics Inc. (ARQT) ahead of earnings
Tweet Send to a Friend
Jefferies analyst Kambiz Yazdi reiterated a Buy rating and $39.00 price target on Arcutis Biotherapeutics Inc. (NASDAQ: ARQT).The analyst comments ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE




